Skip to main content

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

Publication ,  Journal Article
Felker, GM; Fiuzat, M; Shaw, LK; Clare, R; Whellan, DJ; Bettari, L; Shirolkar, SC; Donahue, M; Kitzman, DW; Zannad, F; Piña, IL; O'Connor, CM
Published in: Circ Heart Fail
January 2012

BACKGROUND: Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study. METHODS AND RESULTS: HF-ACTION was a randomized, controlled trial of exercise training in patients with chronic heart failure caused by left ventricular systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. Higher galectin-3 levels were associated with other measures of heart failure severity, including higher New York Heart Association class, lower systolic blood pressure, higher creatinine, higher amino-terminal proB-type natriuretic peptide (NTproBNP), and lower maximal oxygen consumption. In unadjusted analysis, there was a significant association between elevated galectin-3 levels and hospitalization-free survival (unadjusted hazard ratio, 1.14 per 3-ng/mL increase in galectin-3; P<0.0001). In multivariable modeling, the prognostic impact of galectin-3 was significantly attenuated by the inclusion of other known predictors, and galectin-3 was no longer a significant predictor after the inclusion of NTproBNP. CONCLUSIONS: Galectin-3 is elevated in ambulatory heart failure patients and is associated with poor functional capacity and other known measures of heart failure severity. In univariate analysis, galectin-3 was significantly predictive of long-term outcomes, but this association did not persist after adjustment for other predictors, especially NTproBNP. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

January 2012

Volume

5

Issue

1

Start / End Page

72 / 78

Location

United States

Related Subject Headings

  • Severity of Illness Index
  • Prognosis
  • Predictive Value of Tests
  • Peptide Fragments
  • Oxygen Consumption
  • Outpatients
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Felker, G. M., Fiuzat, M., Shaw, L. K., Clare, R., Whellan, D. J., Bettari, L., … O’Connor, C. M. (2012). Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail, 5(1), 72–78. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963637
Felker, G Michael, Mona Fiuzat, Linda K. Shaw, Robert Clare, David J. Whellan, Luca Bettari, Shailesh C. Shirolkar, et al. “Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Circ Heart Fail 5, no. 1 (January 2012): 72–78. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963637.
Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012 Jan;5(1):72–8.
Felker, G. Michael, et al. “Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Circ Heart Fail, vol. 5, no. 1, Jan. 2012, pp. 72–78. Pubmed, doi:10.1161/CIRCHEARTFAILURE.111.963637.
Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O’Connor CM. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012 Jan;5(1):72–78.

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

January 2012

Volume

5

Issue

1

Start / End Page

72 / 78

Location

United States

Related Subject Headings

  • Severity of Illness Index
  • Prognosis
  • Predictive Value of Tests
  • Peptide Fragments
  • Oxygen Consumption
  • Outpatients
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Humans